These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

540 related items for PubMed ID: 18848553

  • 1. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.
    Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P.
    Gastroenterology; 2008 Nov; 135(5):1493-9. PubMed ID: 18848553
    [Abstract] [Full Text] [Related]

  • 2. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [Abstract] [Full Text] [Related]

  • 3. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.
    Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D'Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF.
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1296-309. PubMed ID: 20298496
    [Abstract] [Full Text] [Related]

  • 5. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF.
    Gastroenterology; 2007 Jan; 132(1):52-65. PubMed ID: 17241859
    [Abstract] [Full Text] [Related]

  • 6. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
    Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF.
    Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
    [Abstract] [Full Text] [Related]

  • 7. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
    Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J.
    Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881
    [Abstract] [Full Text] [Related]

  • 8. Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease.
    Sandborn WJ, Colombel JF, D'Haens G, Plevy SE, Panés J, Robinson AM, Pollack PF, Zhou Q, Castillo M, Thakkar RB.
    Curr Med Res Opin; 2013 May; 29(5):483-93. PubMed ID: 23438483
    [Abstract] [Full Text] [Related]

  • 9. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P, Van Assche G, Sandborn WJ, Wolf DC, Geboes K, Colombel JF, Reinisch W, EXTEND Investigators, Kumar A, Lazar A, Camez A, Lomax KG, Pollack PF, D'Haens G.
    Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW, Lawrance IC.
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
    Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, Ponsioen CI, van Dullemen HM, Russel M, van Bodegraven AA, van der Woude CJ.
    Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C, Ascolani M, Pallone F, Biancone L.
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [Abstract] [Full Text] [Related]

  • 13. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
    Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P.
    Gastroenterology; 2006 Feb; 130(2):323-33; quiz 591. PubMed ID: 16472588
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GB.
    Ann Intern Med; 2012 Dec 18; 157(12):846-55. PubMed ID: 23247938
    [Abstract] [Full Text] [Related]

  • 15. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R.
    J Crohns Colitis; 2013 Dec 18; 7(12):958-67. PubMed ID: 23517933
    [Abstract] [Full Text] [Related]

  • 16. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, Pfefferkorn MD, Kelleher KT, Griffiths AM, Kugathasan S, Keljo D, Oliva-Hemker M, Crandall W, Carvalho RS, Mack DR, Hyams JS.
    Am J Gastroenterol; 2009 Dec 18; 104(12):3042-9. PubMed ID: 19724267
    [Abstract] [Full Text] [Related]

  • 17. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
    Riis A, Martinsen TC, Waldum HL, Fossmark R.
    Scand J Gastroenterol; 2012 Jun 18; 47(6):649-57. PubMed ID: 22472026
    [Abstract] [Full Text] [Related]

  • 18. Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres.
    Mandel MD, Balint A, Golovics PA, Vegh Z, Mohas A, Szilagyi B, Szabo A, Kurti Z, Kiss LS, Lovasz BD, Gecse KB, Farkas K, Molnar T, Lakatos PL.
    Dig Liver Dis; 2014 Nov 18; 46(11):985-90. PubMed ID: 25156871
    [Abstract] [Full Text] [Related]

  • 19. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
    Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P.
    Gastroenterology; 2009 Nov 18; 137(5):1628-40. PubMed ID: 19664627
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
    Wyneski MJ, Green A, Kay M, Wyllie R, Mahajan L.
    J Pediatr Gastroenterol Nutr; 2008 Jul 18; 47(1):19-25. PubMed ID: 18607264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.